ADMA
ADMA Biologics, Inc.
ADMA has the edge over NVO overall, supported by stronger fundamentals and stronger valuation.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
ADMA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
ADMA's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ADMA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $10.76 | -19% |
| Forward | 16x | $13.24 | — |
| Current | 17x | $13.24 | — |
| Fair | 21x | $16.22 | +23% |
| Expensive | 66x | $50.55 | +282% |
Historical ranges are pointers, not guarantees.
ADMA's PE is in its cheap range at 17x. If earnings grow as analysts expect, today's price would be 16x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over ADMA in the historical PE scenario, which offers more potential upside but is not a forecast.
ADMA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
ADMA has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ADMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.81 | +5.6% |
| Q3 2026 | $0.77 | -9.4% |
| Q2 2026 | $0.70 | -18% |
| Q1 2026 | $0.68 | -19% |
| Q4 2025 | $0.60 | -26% |
| Q3 2025 | $0.85 | +204% |
| Q2 2025 | $0.85 | +507% |
| Q1 2025 | $0.84 | +$0.86 |
| Q4 2024 | $0.81 | +$0.94 |
ADMA earned $0.77 per share over the past year, down 9.4% from the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over ADMA on earnings, with more consistent year-over-year improvement.
ADMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $141.1M | +5.1% |
| Q2 2026 | $124.4M | +2% |
| Q1 2026 | $114.5M | -0.3% |
| Q4 2025 | $139.2M | +18% |
| Q3 2025 | $134.2M | +12% |
| Q2 2025 | $122M | +14% |
| Q1 2025 | $114.8M | +40% |
| Q4 2024 | $117.5M | +59% |
ADMA's revenue is growing: $141M last quarter, up 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 48% | +10 points |
| Q2 2026 | 42% | +7.1 points |
| Q1 2026 | 51% | +21 points |
| Q4 2025 | 45% | +13 points |
| Q3 2025 | 38% | +4.9 points |
| Q2 2025 | 35% | -1.5 points |
| Q1 2025 | 30% | +3.7 points |
| Q4 2024 | 33% | +13 points |
ADMA has the edge over NVO on profitability, with a higher operating margin.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over ADMA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
ADMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $15.4M | +$16.4M |
| Q2 2026 | $27.3M | +46% |
| Q1 2026 | $55.7M | +$80.1M |
| Q4 2025 | $34.6M | -27% |
| Q3 2025 | -$1.1M | -104% |
| Q2 2025 | $18.7M | -57% |
| Q1 2025 | -$24.4M | -$19.8M |
| Q4 2024 | $47.5M | +189% |
ADMA has burned cash in most quarters: $133M over the past year, about three times what it generated the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over ADMA on cash flow, with more consistent year-over-year improvement.
ADMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -4.5M shares |
| 1 year | -7.7% | -18.8M shares |
| 3 years | -3.4% | -7.9M shares |
| 5 years | +77% | +98.4M shares |
| Available history | +206% | +152M shares |
ADMA has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $25.1M |
| Q2 2026 | $25.1M |
| Q1 2026 | $130.2M |
| Q4 2025 | $8.9M |
ADMA spent $189M buying back its own shares over the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ADMA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
ADMA has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ADMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.1 | Neutral |
| Stochastic | 85.4 | Overbought |
ADMA's weekly RSI is 69 (neutral) and its Stochastic is 85 (overbought).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ADMA PE vs Healthcare Sector
| Metric | ADMA | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 34% below |
| PE % | 28 | 29 | 1 pt below |
ADMA is trading at 17x earnings, a 34% discount to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over ADMA on valuation relative to its sector.
ADMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.0 | 20% above |
| 20 week MA | $9.91 | 34% above |
| 50 week MA | $12.0 | 10% above |
| 100 week MA | $14.9 | 11% below |
| 200 week MA | $11.4 | 17% above |
ADMA has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
ADMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.95 | $2.15 | -46% |
| 2021 | $2.15 | $1.27 | -41% |
| 2022 | $1.27 | $3.65 | +187% |
| 2023 | $3.65 | $4.52 | +24% |
| 2024 | $4.52 | $17.5 | +286% |
| 2025 | $17.5 | $19.3 | +10% |
| 2026 YTD | $19.3 | $13.2 | -31% |
ADMA's yearly returns have swung widely, from +286% in 2024 to −46% in 2020. It's down 31% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over ADMA on returns for 2026, with the stronger performance.